17/gen/2019 10:34:22 Global Market Estimates Research & Consultants Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Atopic Dermatitis Drugs Market Insights

The Global Atopic Dermatitis Drugs market is expected to grow at a significant CAGR during the forecast period. Factors such as rising prevalence of atopic dermatitis in infants and awareness about the availability of treatments for the disease are expected to drive growth in the atopic dermatitis drugs market during the forecast period. Further, initiatives taken by the Government to provide affordable treatment for atopic dermatitis in emerging economies is expected to positively affect the demand for atopic dermatitis drugs

However, factors such as high cost of biologics drugs for atopic dermatitis is expected to have a negative impact on the market up to a certain extent.

Atopic Dermatitis Drugs market


Request a free sample of this report @: https://www.globalmarketestimates.com/atopic-dermatitis-drugs-market/

Atopic Dermatitis Drugs Market: Drug Class Insights

On the basis of drug class, the Atopic Dermatitis Drugs market can be classified into Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, and Biologics among others. Corticosteroids are expected to hold the largest market share in terms of revenue during the forecast period, being the first-line therapy. PDE4 Inhibitors and Biologics segments are expected to grow at a significant CAGR owing to growing adoption of targeted therapy. The Biologics segment is however expected to hold a smaller market share, as it is a drug prescribed when the patient does not respond to any first-line treatment drugs.

Atopic Dermatitis Drugs Market: Mode of Administration Insights

The Global Atopic Dermatitis Drugs market is segmented into Topical, Oral, and Injectable based on the mode of administration. The topical drugs segment is projected to hold the largest market share in terms of revenue. The injectable drugs segment is expected to grow at the highest CAGR during the forecast period owing to the development of new technology and new product launches.

Atopic Dermatitis Drugs Market: Regional Insights

North America is expected to hold the largest market share in terms of revenue, which is dominated by the U.S. Rising incidence of atopic dermatitis and awareness about advanced drugs are expected to boost the demand for atopic dermatitis drugs in the region. The Asia Pacific region is expected to grow at the highest CAGR owing to high population and rising awareness about healthcare in the region. Japan is projected to contribute significantly to growth in the Asia Pacific market for atopic dermatitis.

Atopic Dermatitis Drugs market

Atopic Dermatitis Drugs  Market: End-Use Landscape

The end-use landscape entails a list of current and prospective consumers prevailing across the regions. This section provides company addresses, contact details, products, and regional presence of companies who are purchasing or are likely to purchase controlled release fertilizer over the coming years. Some leading consumers of controlled release fertilizer are LifePoint Health, CVS Corporation, and Cipla among others.

Atopic Dermatitis Drugs  Market: Vendor Landscape

The report contains a chapter dedicated to vendors operating in the market, covering raw material manufactures, equipment developers, manufacturers, and distributors. The report provides these insights on a regional level. This section of the report entails contact details, experience, products manufactured/supplied, and geographical presence of companies.

Atopic Dermatitis Drugs  Market: Share & Competitor Analysis

Some of the key players operating in the Atopic Dermatitis Drugs market are Bayer, LEO Pharma, Mylan, Pfizer, and Sanofi among others.

Sanofi is expected to launch a new Antibody Drug Dupilumab for Atopic Dermatitis in late 2018.

In March 2017, the U.S. Food & Drug Administration approved the drug Dupizent, which is an injectable drug used to treat atopic dermatitis in adults.

In December 2016, thee U.S. FDA approved its EUCRISATM (crisaborole) ointment 2%,, a drug used for moderate atopic dermatitis in children.

Browse this report @: https://www.globalmarketestimates.com/atopic-dermatitis-drugs-market/

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl